Andrew Cittadine, Chief Operating Officer at Monopar Therapeutics (MNPR), bought 16,053 shares at $3.00 ($50K) on 2022-11-14, disclosed to the SEC on 2022-11-16.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.00 | 6,053 | $18K | 36.6% |
| 2 | $3.15 | 10,000 | $32K | 63.4% |
| Total | $3.09 avg | 16,053 | $50K | 100% |
| Filing → |
| MNPR | BUY | 2024-06-05 | $18K | — | Filing → |
| MNPR | BUY | 2024-05-31 | $23K | — | Filing → |